Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?

Background Outcomes-based agreements (OBAs) have the potential to provide more timely patient access to novel therapies, although they are not suitable for every new medication or reimbursement scenario. The authors of this paper studied how to operationalize an OBA in oncology by leveraging existin...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2023-01, Vol.31 (1), p.5-5, Article 5
Main Authors: Cheung, Winson Y., Cameron, Chris, Mitha, Arif, Wills, Allison
Format: Article
Language:English
Subjects:
Alberta
Cancer therapies
Clinical outcomes
Feasibility Studies
Health aspects
Health informatics
Humans
Infrastructure
Infrastructure (Economics)
Medical Oncology
Medicine
Medicine & Public Health
Neoplasms - therapy
Nursing
Nursing Research
Oncology
Pain Medicine
Patient Reported Outcome Measures
Rehabilitation Medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Outcomes-based agreements (OBAs) have the potential to provide more timely patient access to novel therapies, although they are not suitable for every new medication or reimbursement scenario. The authors of this paper studied how to operationalize an OBA in oncology by leveraging existing real-world data (RWD) infrastructure in the province of Alberta. Objective The main objectives were to (1) evaluate which health outcomes in oncology are suitable for OBAs and whether they can be tracked with existing infrastructure, and (2) determine how RWD in oncology can be used to implement an OBA and the expected timing for delivery. Methods Using the Oncology Outcomes (O2) Group infrastructure and Alberta administrative data, a review of five key oncology outcomes was performed to determine suitability to support an OBA. Results Overall survival and time-to-next-treatment were determined as potentially suitable oncology outcomes for OBAs; progression-free survival, patient-reported outcomes, and return to work were deemed inadequate for OBAs at the current time due to data limitations. Conclusions Results indicate that it is feasible to leverage RWD to support OBAs in oncology in Alberta, with minimal additional data, resources, and infrastructure. The operational processes and steps to collect and analyze RWD for OBAs were identified, starting with performing an RWD feasibility study. The expected timeframe to fulfill the real-world evidence (RWE) requirements for an OBA is approximately 3 years for cancers with short trajectories.
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-022-07486-5